U
TGTX icon

UBS’s TG Therapeutics TGTX Stock Holding History

UBS’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$96K Buy
9,000
+6,000
+200% +$55.6K ﹤0.01% 6050
2014
Q2 		$28K Sell
3,000
-2,838
-49% -$18.1K ﹤0.01% 7657
2014
Q1 		$40K Buy
5,838
+3,733
+177% +$22.1K ﹤0.01% 7153
2013
Q4 		$8K Sell
2,105
-345
-14% -$1.39K ﹤0.01% 9200
2013
Q3 		$12K Buy
+2,450
New +$15K ﹤0.01% 8651

Other funds holding TGTX

BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS's TGTX Position: Q3 2014 in Review

UBS increased its TG Therapeutics (TGTX) stake by 200% in Q3 2014, buying an estimated $55.6K and bringing the position to 9,000 shares worth $96K. The position accounts for ﹤0.01% of the portfolio, ranked #6050.

UBS first reported a position in TGTX in Q3 2013 and has held it in 5 quarters since. 66 funds tracked by Wall St. Rank hold TGTX as of Q3 2014.

  • UBS held 9,000 shares of TG Therapeutics worth $96K as of Q3 2014.
  • UBS bought 6,000 TG Therapeutics shares in Q3 2014, an estimated $55.6K.
  • TG Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6050 holding.
  • UBS first reported a position in TG Therapeutics in Q3 2013 and has held it in 5 quarters since.
  • 66 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.